Becton Dickinson and Co (BDX) Releases Earnings Results, Beats Expectations By $0.17 EPS

Becton Dickinson and Co (BDX) reported quarterly earnings results on Thursday, May-5-2016. The company said it had a profit of $2.18 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.17. Analysts had a consensus of $2.01. The company posted revenue of $3067.00 million in the period, compared to analysts expectations of $3073.41 million. The company’s revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 EPS.

Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Upgraded by Deutsche Bank on Feb 11, 2016 to ” Buy”, Firm has raised the Price Target to $ 163 from a previous price target of $155 .

Becton Dickinson and Co opened for trading at $159.94 and hit $162.25 on the upside on Wednesday, eventually ending the session at $161.6, with a gain of 0.73% or 1.17 points. The heightened volatility saw the trading volume jump to 16,03,085 shares. Company has a market cap of $34,230 M.

In a different news, on Dec 14, 2015, Stephen Sichak (Executive Vice President) sold 8,670 shares at $152.21 per share price. According to the SEC, on Dec 9, 2015, William A Kozy (Executive Vice President) sold 15,495 shares at $154.43 per share price. On Dec 8, 2015, Vincent A Forlenza (Chairman, CEO and President) sold 17,762 shares at $153.10 per share price, according to the Form-4 filing with the securities and exchange commission.

Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.

Becton Dickinson and Co

Leave a Reply

Becton Dickinson and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Becton Dickinson and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.